Cleared Traditional

K883662 - BERICHROM ANTITHROMBIN III

K883662 is the FDA 510(k) clearance for BERICHROM ANTITHROMBIN III by Behring Diagnostics, Inc.. It is a Class 2 Hematology device (product code JBQ) cleared through the Traditional 510(k) pathway after a 89-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1988
Decision
89d
Days
Class 2
Risk

K883662 is an FDA 510(k) clearance for the BERICHROM(R) ANTITHROMBIN III. Classified as Antithrombin Iii Quantitation (product code JBQ), Class II - Special Controls.

Submitted by Behring Diagnostics, Inc. (Somerville, US). The FDA issued a Cleared decision on November 23, 1988 after a review of 89 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7060 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Behring Diagnostics, Inc. devices

Submission Details

510(k) Number K883662 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 26, 1988
Decision Date November 23, 1988
Days to Decision 89 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
24d faster than avg
Panel avg: 113d · This submission: 89d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JBQ Antithrombin Iii Quantitation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7060
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - JBQ Antithrombin Iii Quantitation

All 39
Devices cleared under the same product code (JBQ) and FDA review panel - the closest regulatory comparables to K883662.
ORTHOKROME* ANTITHROMBIN
K900400 · Ortho Diagnostic Systems, Inc. · Mar 1990
ACTICHROME ATIII KIT
K893608 · American Diagnostic Corp. · Jun 1989
TURBOX ANTITHROMBIN III
K884144 · Unipath , Ltd. · Dec 1988
ENZYGNOST(R) TAT REAGENTS
K880700 · Behring Diagnostics, Inc. · Apr 1988
DADE ANTITHROMBIN III CHROMOGENIC ASSAY
K880315 · Baxter Healthcare Corp · Mar 1988
IL TEST 97574-15M, ANTITTHROMBIN III ASSASY
K864214 · Instrumentation Laboratory CO · Nov 1986